---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-008500"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:25:55.210873+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# HeartSciences Q3 no revenue, $1.9M cash; progresses MyoVista FDA clearance, adopts equity plan

## Summary
- No meaningful Q3 FY2023 revenues; cash and equivalents $1.9M as of Jan 31, 2023.
- MyoVista pivotal validation study enrollment progressing for FDA De Novo resubmission; additional enrichment patients enrolled.
- Board adopted 2023 Equity Incentive Plan, subject to stockholder approval, covering employees, directors, and consultants.
- Collaboration with Rutgers University for AI-based ECG algorithms; patent portfolio now 40 (9 U.S., 31 international).
- Appointed microcap veteran David R. Wells to Board of Directors.

## SEC filing metadata
- accession: 0000950170-23-008500
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017023008500/0000950170-23-008500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017023008500/hscs-20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-008500
- JSON: https://secwatch.observer/filing/0000950170-23-008500.json
- Plain text: https://secwatch.observer/filing/0000950170-23-008500.txt

## Key facts
- Earnings Releases
  HeartSciences Inc. reported the fiscal 2023 third quarter ended January 31, 2023 results: revenue no meaningful revenues.
  - Period: the fiscal 2023 third quarter ended January 31, 2023
  - Revenue: no meaningful revenues
  - Result: reported results
  source text: Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company") , a medical technology company focused on saving lives by making an ECG (also known as an EKG) a more valuable screening tool through the use of Artificial Intelligence (AI), today provided a business update and reported financial results for the fiscal 2023 third quarter ended January 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468492/000095017023008500/0000950170-23-008500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.